Update, 29.4.2024
Octapharma wishes to update our stakeholders regarding the recent event affecting our plasma donation centers in the USA.
Thanks to the efforts of our Octapharma Plasma USA and Global IT teams, all our plasma donation centers in the USA have been fully operational again since April 25. Our production sites were not impacted by this event, and we have been able to maintain our normal production schedules of our life-saving therapies as planned.
Octapharma was founded in 1983 with the aims of bringing new innovations to the plasma fractionation industry, and manufacturing a higher quality, virally safe FVIII concentrate for hemophilia A patients. Since our founding in 1983, we have grown to provide our life-saving therapies to millions of patients around the world who are dependent on plasma derived therapies to live a normal life.
Octapharma remains committed to safeguarding the information of our donors, employees, and other stakeholders. Octapharma is committed to the highest levels of integrity and ethical conduct, and we will continue to live these values in the future. Compliance with applicable data protection law, such as the European and US data protection laws and regulations, and their equivalent frameworks in other countries where we operate, remains one of our highest priorities.
We continue to investigate this event in consultation with outside experts and the relevant authorities, and will provide further updates as appropriate.
